Current-day precision oncology: from cancer prevention, screening, drug development, and treatment – have we fallen short of the promise?

Purpose of review: Precision oncology has been a strategy of prevention, screening, and treatment. Although much has been invested, have the results fallen so far short of the promise? The advancement of technology and research has opened new doors, yet a variety of pitfalls are present. This review presents the successes, failures, and opportunities of precision oncology in the current landscape. Recent findings: The use of targeted gene sequencing and the overwhelming results of superresponders have generated much excitement and support for precision oncology from the medical community. Despite notable successes, many challenges still pave the way of precision oncology: intratumoral heterogeneity, the need for serial biopsies, availability of treatments, target prioritization, ethical issues with germline incidental findings, medical education, clinical trial design, and costs. Summary: Precision oncology shows much potential through the use of next-generation sequencing and molecular advances, but does this potential warrant the investment? There are many obstacles on the way of this technology that should make us question if the investment (both monetary and man-hours) will live up to the promise. The review aims to not criticize this technology, but to give a realistic view of where we are, especially regarding cancer treatment and prevention.
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: INNOVATIVE AGENTS AND TREATMENT MODALITIES: Edited by Ahmad Awada Source Type: research

Related Links:

Publication date: Available online 17 November 2019Source: European UrologyAuthor(s): Zhengzheng Xu, Guangzhe Ge, Bao Guan, Zhentao Lei, Xueyu Hao, Yuanyuan Zhou, Yue Shi, Huan Lu, Jilu Wang, Ding Peng, XiKang Wu, Huiying He, Bao Zhang, Xuesong Li, Liqun Zhou, Weimin Ci
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 16 November 2019Source: European UrologyAuthor(s): Pirus Ghadjar, Thomas Wiegel
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 16 November 2019Source: European UrologyAuthor(s): Elise De Bleser, Piet Ost
Source: European Urology - Category: Urology & Nephrology Source Type: research
ConclusionsTattooing of axillary LNs is safe and easily performed. Tattooing was helpful in identifying the marked LN in the majority of cases. This technique helps to ensure that metastatic LNs are identified and removed at surgery after NAT.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Individuals who have multiple close relatives with pancreatic cancer should undergo surveillance for pancreatic cancer, according to updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium.Reuters Health Information
Source: Medscape General Surgery Headlines - Category: Surgery Tags: Hematology-Oncology News Source Type: news
Publication date: Available online 16 November 2019Source: Gynecologic Oncology ReportsAuthor(s): Hermineh Aramin, Pratistha Koirala, Abhishek Shah, Kendall Adams, Natalia Buza, Sapna Desai, Melissa Fairbairn, David Goldenberg, Wenli Gao, Linus Chuang, Ramapriya Vidhun, Vaagn Andikyan
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
Publication date: Available online 17 November 2019Source: Pharmacological ResearchAuthor(s): Ali Dehshahri, Milad Ashrafizadeh, Elham Ghasemipour Afshar, Abbas Pardakhty, Ali Mandegary, Reza Mohammadinejad, Gautam SethiAbstractTopoisomerase enzymes have shown unique roles in replication and transcription. These enzymes which were initially found in Escherichia coli have attracted considerable attention as target molecules for cancer therapy. Nowadays, there are several topoisomerase inhibitors in the market to treat or at least control the progression of cancer. However, significant toxicity, low solubility and poor pharm...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 16 November 2019Source: Journal of Evidence Based Dental PracticeAuthor(s): Walter J. Psoter, Erin T. Shope
Source: Journal of Evidence Based Dental Practice - Category: Dentistry Source Type: research
ConclusionsOral HPV infection is significantly prevalent and widespread worldwide, particularly among men and among populations at risk. Prevalence has increased during the last two decades.
Source: Journal of Evidence Based Dental Practice - Category: Dentistry Source Type: research
In conclusion, miR-142-3p overexpression may inhibit autophagy and promote the drug sensitivity of breast cancer cells to DOX by targeting HMGB1. The miR-142-3p/HMGB1 axis might be a novel target to regulate the drug resistance of breast cancer patients.Graphical abstractHigh-mobility group box 1 (HMGB1) is a direct functional target of miR-142-3p in breast cancer cells. MiR-142-3p overexpression may inhibit autophagy and promote the drug sensitivity of doxorubicin (DOX) by targeting HMGB1. The miR-142-3p/HMGB1 axis might be an important pathway regulating the sensitivity of breast cancer cells.
Source: Acta Pharmaceutica Sinica B - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Education | Genetics | Medical Ethics | Universities & Medical Training